NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

The NOA-03 trial explored high-dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole-brain radiotherap...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Herrlinger, U, Küker, W, Uhl, M, Blaicher, H, Karnath, H, Kanz, L, Bamberg, M, Weller, M
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: 2005

Những quyển sách tương tự